ERBB2 and head and neck squamous cell carcinoma: E7130 also exerted significant and dose-dependent antitumour activities with tumour regression in KPL-4 HER2-positive breast cancer and OSC-19 squamous cell carcinoma of the head and neck (SCCHN) s.c. xenograft models (Supplementary Fig. S1c,d).